Practical recommendations for familial combined hyperlipidemia diagnosis and management: An update

Vascular Disease Prevention

Volumn 4, Issue 3, 2007, Pages 229-236

  Gaddi, Antonio V ^a,e   Cicero, Arrigo F G ^a   Odoo, Fred O ^b   Poli, Andrea ^c   Paoletti, Rodolfo ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c Nutrition Foundation of Italy   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diagnosis; Familial combined hyperlipidemia; Guidelines; Management

Indexed keywords

APOLIPOPROTEIN B100; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; RESIN; VERY LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FAMILIAL HYPERLIPEMIA; FATTY LIVER; HUMAN; HYPERLIPOPROTEINEMIA; LABORATORY TEST; LIFESTYLE MODIFICATION; LIPID METABOLISM; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 34547809965     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727007781388046     Document Type: Review

References (91)

1. Lenzi S, Bucci A, Crepaldi G, et al. The CNR program of preventive medicine--SP4 Objective 44. Non-invasive techniques for the evaluation of atherosclerotic plaque progression or regression. Monogr Atheroscler 1986; 14: 83-90.
2. Gaddi A, Cicero AFG, Nascetti S, Poli A, Inzitari D; on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis. Cerebrovascular disease in Italy and Europe: it is necessary to prevent a "pandemia". Gerontology 2003; 49: 69-79.
3. Gaddi A, Galetti C, Pauciullo P, Arca M; on behalf of the Committee of experts of the Atherosclerosis and Dysmetabolic Disorders Study Group. Familial combined hyperlipoproteinemia: expert panel position on diagnostic criteria for clinical practice. Nutr Metab Cardiovasc Dis 1999; 9: 304-11.
4. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary artery disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52: 1544-1568.
5. Sniderman AD, Castro Cabezas M, Ribalta J, et al. A proposal to redefine familial combined hyperlipidaemia - Third workshop on FCH held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation. Eur J Clin Invest 2002; 32: 71-73.
6. Kwiterovich PO. HyperapoB: a pleiotropic phenotype characterized by dense low density lipoproteins and associated coronary artery disease. Clin Chem 1998; 34: B71-B77.
7. Sniderman AD, Ribalta J, Castro Cabezas M. How should FCH be defined and how should we think about its metabolic bases? Nutr Metab Cardiovasc Dis 2001; 11: 259-273.
8. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglyceride and LDL heterogeneity in familial combined Hyperlipidemia. Arterioscler Thromb 1993; 13:427-434.
9. Venkatesan S, Cullen P, Pacy P, Halliday D, Scott J. Stable isotopes show a direct relation between VLDL Apo B overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 1993; 13: 1110-1118.
10. Meijssen S, Derksen RJ, Bilecen S, Erkelens DW, Castro Cabezas M. In vivo modulation of plasma free fatty acids in patients with Familial Combined Hyperlipidemia using lipid-lowering medication. J Clin Endocrinol Metab 2002; 87: 1576-1580.
11. Verseyden C, Meijssen S, Castro Cabezas M. Postprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemia. J Lipid Res 2002; 43: 274-280.
12. Campagna F, Montali A, Baroni MG, et al. Common variants in the lipoprotein lipase gene, but not those in the insulin receptor substrate-1, the beta3-adrenergic receptor, and the intestinal fatty acid binding protein-2 genes, influence the lipid phenotypic expression in familial combined hyperlipidemia. Metabolism 2002; 51: 1298-305.
13. Aouizerat BE, Allayee H, Cantor RM, et al. Linkage of a candidate gene locus to familial combined hyperlipidemia: lecithin: cholesterol acyltransferase on 16q. Arterioscler Thromb Vasc Biol 1999; 19: 2730-6.
14. Pihlajamaki J, Karjalainen L, Karhapaa P, et al. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2000; 20: 1789-95.
15. van der Kallen CJ, Voors-Pette C, de Bruin TW. Abdominal obesity and expression of familial combined hyperlipidemia. Obes Res 2004; 12: 2054-61.
16. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002; 22: 811-816.
17. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA, Motulsky AG, Brunzell JD. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2003; 23: 1289-1294.
18. Vakkilainen J, Pajukanta P, Cantor RM, et al. Genetic influences contributing to LDL particle size in familial combined hyperlipidaemia. Eur J Hum Genet 2002; 10: 547-552.
19. Kissebah AH, Alfarsi S, Evans DJ. LDL metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis 1984; 4: 614-624.
20. Kane JP, Havel RJ. Disorders of biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly W, Valle D (eds) The metabolic basis of inherited disease. New York: McGraw-Hill Inc.; 1989: 1129-1164.
21. Williams KJ, Petrie A, Brocia RW, Swenson TL. Lipoprotein lipase modulates net secretory output of apolipoprotein B in vitro: a possible pathophysiologic explanation for familial combined Hyperlipidemia. J Clin Invest 1991; 88: 1300-1306.
22. Liu ML, Ylitalo K, Vakkilainen J, et al. Susceptibility of LDL to oxidation in vitro and antioxidant capacity in familial combined hyperlipidemia: comparison of patients with different lipid phenotypes. Ann Med 2002; 34: 48-54.
23. Cicero AFG, Panourgia MP, Linarello S, D'Addato S, Sangiorgi Z, Gaddi A. Serum lipoprotein(a) levels in a large sample of subjects affected by familial combined hyperlipoproteinemia (FCH) and in general population. J Cardiovasc Risk 2003; 10: 149-151.
24. Soro A, Jauhiainen M, Ehnholm C, Taskinen MR. Determinants of low HDL levels in familial combined hyperlipidemia. J Lipid Res 2003; 44: 1536-1544.
25. Georgieva AM, van Greevenbroek MM, Krauss RM, et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2004; 24: 744-749.
26. Austin MA, Brunzell J, Fitch WL, Krauss RM. Inheritance of LDL subclass patterns in familial combined hyperlipidemia. Arteriosclerosis 1990; 10: 520-530.
27. Pajukanta P, Nuotio I, Terwilliger JD, et al. Linkage of familial combined hyperlipidaemia to chromosome 1q21q23. Nat Genet 1998; 18: 369-373.
28. Coon H, Myers RH, Borecki IB, et al. Replication of linkage of familial combined hyperlipidemia to chromosome 1q with additional heterogeneous effect of apolipoprotein A-I/C-III/A-IV locus: the NHLBI family heart study. Arterioscler Thromb Vasc Biol 2000; 20: 2275-2280.
29. Pei W, Baron H, Muller-Myhsok B, et al. Support for the linkage of familial combined hyperlipidemia to chromosome 1q21-q23 in Chinese and German families. Clin Genet 2000; 57: 29-34.
30. Allayee H, Krass KL, Pajukanta P, et al. Locus for elevated apolipoprotein B levels on Chromosome 1p31 in families with familial combined hyperlipidemia. Circ Res 2002; 90: 926-931.
31. Elbein SC, Hoffman MD, Teng K, Leppert MNF, Hasstedt SJ. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes 1999; 48: 1175-1182.
32. Wiltshire S, Hattersley AT, Hitman GA, et al. A genomewide scan for loci predisposing to type 2 diabetes in a UK population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q. Am J Hum Genet 2001; 69: 553-569.
33. Eichenbaum-Voline S, Olivier M, Jones EL, et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2004; 24: 167-174.
34. Badzioch MD, Igo RP Jr, Gagnon F, et al. Low-density lipoprotein particle size loci in familial combined hyperlipidemia: evidence for multiple loci from a genome scan. Arterioscler Thromb Vasc Biol 2004; 24: 1942-50.
35. Pajukanta P, Lilja HE, Singheimer JS, et al. Familial Combined hyperlipidemia is associated with upstream transcription factor 1 (USF 1). Nat Genet 2004; 36: 371-376.
36. Corella D, Ordovas JM. Single nucleotide polymorphisms that influence lipid metabolism: Interaction with dietary factors. Annu Rev Nutr 2005; 25: 341-390.
37. Stalenhoef AF. Interaction between genes and environment in inherited lipid disorders determines clinical presentation. Cardiovasc Drugs Ther 2002; 16: 271-272.
38. De Bruin TWA, Castro Cabezas M, Dallinga-Yhie G, Erkelens DW. Familial Combined Hyperlipidaemia - do we understand the pathophysiology and genetics? In: Betteridge DJ ed. Lipids: current perspectives. London: Martin Dunitz; 1996: 101-109.
39. Cicero AFG, Dormi A, Bove M, et al. on behalf of the Brisighella Heart Study group. Estimation of Familial Combined Hyperlipoproteinemia prevalence in a large rural population: the Brisighella Heart Study. Vasc Dis Prev 2007; 4: 185-9.
40. Iwata F, Okada T, Kuromori Y, Hara M, Harada K. Screening for familial combined hyperlipidemia in children using lipid phenotypes. J Atheroscler Thromb 2003; 10: 299-303.
41. Aguilar Salinas CA, Zamora M, Gomez-Diaz RA, Mehta R, Gomez Perez FJ, Rull JA. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med 2004; 4: 203-9.
42. Veerkamp MJ, de Graaf J, Bredie SJH, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Diagnosis of Familial Combined Hyperlipidemia based on lipid phenotype expression in 32 Families. Results of a 5-Year Follow-Up Study. Arterioscler Thromb Vasc Biol 2002; 22: 274-282.
43. del Rincon Jarero JP, Aguilar-Salinas CA, Guillen-Pineda LE, Gomez-Perez FJ, Rull JA. Lack of agreement between the plasma lipid-based criteria and apoprotein B for the diagnosis of familial combined hyperlipidemia in members of familial combined hyperlipidemia kindreds. Metabolism 2002; 51: 218-224.
44. Veerkamp MJ, de Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Normogram to diagnose Familial Combined Hyperlipidemia on the basis of results of a 5-Year follow-up study. Circulation 2004; 109: 2987-2992.
45. Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease. International Atherosclerosis Society. March 2003.
46. Kuromori Y, Okada T, Iwata F, Hara M, Noto N, Harada K. Familial combined hyperlipidemia (FCH) in children: the significance of early development of hyperapoB lipoproteinemia, obesity and aging. J Atheroscler Thromb 2002; 9: 314-20.
47. Hashem A, Chi MT, Friedman CP. Medical errors as a result of specialization. J Biomed Inform 2003; 36: 61-69.
48. De Bruin TWA, Castro Cabezas M, Dallinga-Yhie G, Erkelens DW. Familial Combined Hyperlipidaemia - do we understand the pathophysiology and genetics? In: Betteridge DJ ed. Lipids: current perspectives. London: Martin Dunitz; 1996: 101-109.
49. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
50. de Graaf J, van der Vleuten G, Stalenhoef AF. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 2004; 4: 229-40.
51. Demacker PN, Veerkamp MJ, Bredie SJ, Marcovina SM, de Graaf J, Stalenhoef AF. Comparison of the measurement of lipids and lipoproteins vs. assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis 2000; 153: 483-490.
52. Sveger T, Nordborg K. Apolipoprotein B as a marker of familial hyperlipoproteinemia. J Atheroscler Thromb 2004; 11: 286-92.
53. Delawi D, Meijssen S, Castro Cabezas M. Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta 2003; 328: 139-145.
54. Durrington P. Dyslipidaemia. Lancet 2003; 362: 717-731.
55. Ylitalo K, Syvanne M, Salonen R, Nuotio I, Taskinen MR, Salonen JT. Carotid artery intima-media thickness in Finnish families with familial combined hyperlipidemia. Atherosclerosis 2002; 162: 171-178.
56. Green RM. NASH - hepatic metabolism and not simply the metabolic syndrome. Hepatology 2003; 38: 14-17.
57. de Bruin TW, Georgieva AM, Brouwers MC, Heitink MV, van der Kallen CJ, van Greevenbroek MM. Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. Am J Med 2004; 116: 847-849.
58. Mancuso G, La Regina G, Bagnoli M, et al. "Normolipemic" tendinous and tuberous xanthomatosis. Dermatology 1996; 193: 27-32.
59. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94. Series 1: programs and collection procedures. Vital Health Stat 1994; 32: 1-407.
60. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99: 1-14.
61. Hopkins PN, Heiss G, Ellison RC, et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 2003; 108: 519-23.
62. Gaddi AV, Cicero AFG. Metabolic syndromes: diagnosis, prognosis, therapy. Esculapio Ed., Bologna, Italy, 2006; 145-152.
63. Veerkamp MJ, de Graaf J, Stalenhoef AF. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2005; 25: 1026-31.
64. de Graaf J, van der Vleuten G, Stalenhoef AF. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 2004; 4: 229-40.
65. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003; 92(4A): 27J-33J.
66. American Diabetes Association. Standards of Medical Care in Diabetes-2006. Diabetes Care 2006; 29(S1): S4-S42.
67. Cicero AFG, Martini C, Nativio V, Reggiani A, Dormi A, Gaddi A. Association between lipidic phenotype variability and CHD/CVD in a large rural population: the Brisighella Study. Atherosclerosis 2000; 151: 105.
68. Keulen ET, Kruijshoop M, Schaper NC, Hoeks AP, de Bruin TW. Increased intima-media thickness in familial combined hyperlipidemia associated with apolipoprotein B. Arterioscler Thromb Vasc Biol 2002; 22: 283-288.
69. Liu ML, Ylitalo K, Nuotio I, Salonen R, Salonen JT, Taskinen MR. Association between carotid intima-media thickness and lowdensity lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 2002; 33: 1255-1260.
70. Pitkanen OP, Nuutila P, Raitakari OT, et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation 1999; 99: 1678-1684.
71. Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation 2000; 101: 2777-2782.
72. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90(10C): 18L-21L.
73. Civeira F. For the International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173(1): 55-68.
74. Forster LF, Stewart G, Bedford D, et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with the low VLDL and LDL fractional clearance rates. Atherosclerosis 2002; 164:129-145.
75. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170: 315-23.
76. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95: 462-468.
77. ter Avest E, Abbink EJ, Holewijn S, de Graaf J, Tack CJ, Stalenhoef AF. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr Med Res Opin 2005; 21: 1469-76.
78. Blanco-Colio LM, Martin-Ventura JL, Sol JM, Diaz C, Hernandez G, Egido J. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol 2004; 43: 1188-1194.
79. Sirtori CR, Calabresi L, Pisciotta L, et al. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. Nutr Metab Cardiovasc Dis 2005; 15: 47-55.
80. Bredie SJ, Westerveld HT, Knipscheer HC, de Bruin TW, Kastelein JJ, Stalenhoef AF. Effects of gemfibrozil or simvastatin on apolipoprotein-B- containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Neth J Med 1996; 49: 59-67.
81. Tato F, Keller C, Wolfram G. Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia. Clin Investig 1993; 71(4): 314-318.
82. Abbink EJ, De Graaf J, De Haan JH, Heerschap A, Stalenhoef AF, Tack CJ. Effects of pioglitazone in familial combined hyperlipidaemia. J Intern Med 2006; 259: 107-116.
83. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother 2003; 4: 1901-1938.
84. Verseyden C, Meijssen S, Cabezas MC. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia. J Clin Endocrinol Metab 2004; 89: 5021-9.
85. Insua A, Massari F, Rodriguez Moncalvo JJ, Ruben Zanchetta J, Insua AM. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 2002; 8: 96-101.
86. Calabresi L, Villa B, Canavesi M, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 2004; 53: 153-158.
87. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005; 95(4): 462-8.
88. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45: 1649-53.
89. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003; 25: 2352-2387.
90. Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005; 21: 1123-1130.
91. Elam MB, Hunninghake DB, Davis KB. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT trial - a randomized trial. JAMA 2000; 284: 1263-1270.